Cascadia Healthcare

cascadiahc.com

Cascadia was formed when partners from the skilled nursing and real estate development industry joined forces with a common purpose in mind – to provide a high level of care to patients and families within the region they call home. Our goal is to provide a motivating environment for our employees based on the values of quality work, empowerment and accountability. Cascadia is driven by honest hard work and we believe that strong partnerships and quality care are the outcome.

Related News

MEDICAL

BOTANICAL SOLUTION INC. (BSI) SECURES $6.1 MILLION IN SERIES A FIRST CLOSING

Botanical Solution Inc. | January 18, 2022

news image

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. Read More

MEDICAL

HTL ANNOUNCES ITS INCUBATOR'S EQUITY INVESTMENT IN GELMEDIX, AN EARLY-STAGE BIOTECH AIMING AT REVOLUTIONIZING OCULAR AND REGENERATIVE THERAPIES

HTL | March 14, 2022

news image

HTL Biotechnology, a pioneer and world leader in the development and production of innovative pharmaceutical grade biopolymers, today announced its incubator's first equity investment in GelMEDIX Inc., an early-stage biotechnology company committed to developing the next generation of ocular and regenerative therapies. This investment supports continued development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therap...

Read More

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

news image

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More

CELL AND GENE THERAPY

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

news image

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More
news image

MEDICAL

BOTANICAL SOLUTION INC. (BSI) SECURES $6.1 MILLION IN SERIES A FIRST CLOSING

Botanical Solution Inc. | January 18, 2022

Botanical Solution Inc. innovator of sustainable, consistent and cost-effective Advanced Botanical Materials for agricultural and pharmaceutical applications, has successfully closed $6.1 million in a Series A round led by Palo Alto based VC Firm, Otter Capital. This round of funding will enhance BSI’s value proposition by facilitating the geographic expansion of its current botanical-based products and development of a new product pipeline derived from its proprietary biotech platform. Read More

news image

MEDICAL

HTL ANNOUNCES ITS INCUBATOR'S EQUITY INVESTMENT IN GELMEDIX, AN EARLY-STAGE BIOTECH AIMING AT REVOLUTIONIZING OCULAR AND REGENERATIVE THERAPIES

HTL | March 14, 2022

HTL Biotechnology, a pioneer and world leader in the development and production of innovative pharmaceutical grade biopolymers, today announced its incubator's first equity investment in GelMEDIX Inc., an early-stage biotechnology company committed to developing the next generation of ocular and regenerative therapies. This investment supports continued development of the GelMEDIX platform, which enables the delivery of therapeutics from small molecules to cell and gene therap...

Read More
news image

OXITEC UNVEILS FIRST FIELD TRIAL RESULTS FOR CROP-PROTECTING GM MOTHS

Labiotech.eu | January 28, 2020

A study led by Oxitec has shown for the first time that diamondback moths genetically engineered to produce only male offspring can survive in the wild, a solution that shows promise for cutting populations of the crop pest. Caterpillars of the diamondback moth Plutella xylostella are one of the most destructive pests for growers of cabbages, broccoli and cauliflowers. Rising resistance to insecticides is making it progressively more difficult for farmers to deal with the insects effectively....

Read More
news image

CELL AND GENE THERAPY

FULGENT GENETICS ANNOUNCES STRATEGIC INVESTMENT IN SPATIAL GENOMICS

Fulgent Genetics, Inc. | February 24, 2022

Fulgent Genetics, Inc. a technology-based genetic testing company focused on transforming patient care in oncology, infectious and rare diseases, and reproductive health, today announced a strategic investment in Spatial Genomics, Inc. a leading developer of sequential fluorescence in situ hybridization technology. Fulgent Genetics is investing up to $40 million to lead Spatial Genomics’ Series A financing, which totals approximately $56 million and also includes investments by 12 West Cap...

Read More